

# Integrating Undergraduates into Educationally Meaningful Research Programs and Courses

Jeffrey H. Miller


University of California, Los Angeles CA



# Challenge


## Involve Students in Research

### Goals

1. Transmit the excitement of tackling the unknown
  2. Have rapid rewards instead of long apprenticeship
  3. Present an intellectual process
  4. Student has ownership of a project and results, not a “cog in the wheel”
  5. Understand the practical importance of the relevant area of research
- 


# Requirements

- Commitment from mentor
- Commitment from student
- Projects that allow goals to be achieved



Erin R. Sanders-Lorenz and Jeffrey H. Miller

# I, Microbiologist




**A Discovery-Based Course in  
Microbial Ecology and Molecular Evolution**

# Environmental Samples Collected and Source:

Strain	Species	Color	Source
CB001	<i>E. coli</i> strain	Pinkish red	Lab contaminant
CB002	<i>Staphylococcus</i> strain	White	Amie Fong finger
CB003	<i>Bacillus cereus</i>	Salmon	Soil
CB004	<i>Bacillus cereus</i>	Pale yellow	Soil
CB005	<i>Bacillus cereus</i>	Yellow orange	Soil
CB006	<i>Bacillus cereus</i>	Orange	Soil
CB007	<i>Bacillus cereus</i>	Yellow	Amie Fong finger
CB008	<i>Bacillus cereus</i>	Neon red	Amie Fong hair
CB009	<i>E. fergusonii</i> (potentially)	Bloody red/orange	South campus dumpster
CB010	<i>Bacillus cereus</i>	Baby pink	UCLA campus
CB011	<i>Staphylococcus hominis</i>	Tan	Arrowhead water jug from CHS
CB012	<i>Bacillus cereus</i>	Bright red	Orthopaedic hospital bathroom handle
CB013	<i>Staphylococcus</i> strain	White #2	Orthopaedic hospital bathroom handle










# Bacterial Art











**It Takes 1,000 Nanobiologists to Make One Microbiologist**

*- Sydney Brenner*







WT    1. *tolC*  
         2. *tolC recC*

Strain A=WT (yellow)

Strain B=Drug sensitive mutant (purple)

starting mixture

1:20 Strain A: Strain B  
purple



growth without drug



growth in presence of  
drug: strain B inhibited by  
low concentration of drug







LB

Cipro .05

Cipro .1


Cipro .2

Cipro .5

Cipro 1

*WT:tolCrecC*

ng/ml



# What is the minimum concentration of an antibiotic that is significant?

- Current thought holds that evolution of antibiotic resistance occurs at the MIC and above
- Reservoirs of antibiotic resistance already exist
- What is the minimum concentration that selects for resistance? (MSC)





# Competition Experiments

Lac<sup>-</sup> CIP<sup>S</sup> : Lac<sup>+</sup> CIP<sup>R</sup>  
10 : 1




Grow

0, 0.2, 0.5, ... ng/ml CIP

# 24 Generations




CIP 0 ng/ml



CIP  $<0.2$  MIC

## Growth of Tet<sup>r</sup> *E.coli*





# Brazilian amputee model dead at 20



## •STORY HIGHLIGHTS

- **NEW:** Brazilian amputee model Mariana Bridi da Costa died early Saturday
  - Da Costa's hands, feet were amputated after she contracted septicemia
  - Da Costa placed sixth in the Miss Bikini International competition in China

# Family Mourning MRSA Death Of Frankford Teen



Reporting  
Valerie  
Levesque

PHILADELPHIA (CBS 3) — A local family is speaking out after they say their young son died of the highly contagious infection MRSA.

Michael Leterski was a 13-year student at the Ethan Allen Elementary School and a Frankford resident. His family thought he had a bad cold or the flu until he died February 16.

"All of a sudden, he just said 'it's time' and blood just started pouring out of his mouth and he was gone in my arms and my son was doing CPR on him," Michael's grandmother Mary Ann Gwalthney said.

The family told CBS3 that the medical examiner's office did an autopsy.

"They took a part of the lung and put it in the machinery and found out it was MRSA," Mary Ann said. "He was a perfectly healthy, normal 13-year-old boy looking to graduate from school, and just wiped out of our arms."



◀ 1 of 1 ▶

[Click to enlarge](#)

A Frankford family says their son, Michael Leterski, died of MRSA.  
CBS


## Related Slideshows



[World Welcomes Mardi Gras 2009](#)



[Red Carpet Fashions At 81st Academy](#)



*Staphylococcus aureus*



*Mycobacterium tuberculosis*



*Acinetobacter baumannii*



*Pseudomonas aeruginosa*



# Strategy

Screen KEIO collection of ~ 4,000 single gene knockout strains in *E. coli*



Antibiotic

Find hypersensitive mutants

Test counterparts in other bacteria



Determine pathways involved (networks)




Find small molecule inhibitors of proteins involved



Use as co-drugs or potentiators

Ciprofloxacin 0 ng/ml



*fis*

Ciprofloxacin 7.5 ng/ml



*fis*

# Cipro MIC (ng/ml)

WT	16-20	<i>recA</i>	2
<i>fis</i>	6	<i>fis recA</i>	1
<i>ruvC</i>	8	<i>xseA</i>	6
<i>fis ruvC</i>	2	<i>recC</i>	8
<i>tolC</i>	5	<i>xseA recC</i>	1.3
<i>fis tolC</i>	0.2	<i>recC tolC</i>	0.3



# Cipro Resistant Mutant Gyrase A S83L

<u>Background</u>	<u>MIC (ng/ml)</u>
WT	750
<i>recC</i>	500
<i>fis</i>	300
<i>xseA</i>	250
<i>recA</i>	125
<i>tolC</i>	64
<i>tolC recC</i>	20

# Vancomycin MIC ( $\mu\text{g/ml}$ )

WT 500

*surA* 4

*smpA* 70

*surA smpA* 1.5





Gene	CIP	ENX	NIT	MTR	SFX	RIF	GEN	TOB	NEO	STR	SPT	TET	VAN	AMP	RAD	FOX	ATM	CST	CHL	ERY	FUS	TRI	Categ
<i>recA</i>																							1
<i>recB</i>																							1
<i>recC</i>																							1
<i>acrA</i>																							2
<i>acrB</i>																							2
<i>tolC</i>																							2
<i>ddlB</i>																							2
<i>envC</i>																							2
<i>lpxL</i>																							2
<i>lpxM</i>																							2
<i>nlpC</i>																							2
<i>proW</i>																							2
<i>pslS</i>																							2
<i>qmcA</i>																							2
<i>rfaC</i>																							2
<i>rfaD</i>																							2
<i>rfaE</i>																							2
<i>rfaG</i>																							2
<i>taiC</i>																							2
<i>tolR</i>																							2
<i>ybgF</i>																							2
<i>ydcS</i>																							2
<i>dnaK</i>																							2A
<i>hlpA</i>																							2A
<i>hscA</i>																							2A
<i>surA</i>																							2A
<i>rimK</i>																							3
<i>rplA</i>																							3
<i>rpmE</i>																							3
<i>rpmJ</i>																							3
<i>rsmF</i>																							3
<i>yheM</i>																							3
<i>yheN</i>																							3
<i>yfgC</i>																							3
<i>rlmE</i>																							3A
<i>apG</i>																							4
<i>dapF</i>																							4
<i>gmhB</i>																							4
<i>gpmM</i>																							4
<i>iscS</i>																							4
<i>mraW</i>																							4
<i>pgaC</i>																							4
<i>rutA</i>																							4
<i>ycjU</i>																							4
<i>ygcO</i>																							4
<i>dksA</i>																							5
<i>fur</i>																							5
<i>hfq</i>																							5
<i>hns</i>																							5
<i>mfd</i>																							5
<i>nusB</i>																							5
<i>rseA</i>																							5
<i>xapR</i>																							5
<i>yciT</i>																							5
<i>ylcG</i>																							6
<i>ybeD</i>																							7
<i>ybeY</i>																							7
<i>ybhT</i>																							7
<i>ycbW</i>																							7
<i>yciM</i>																							7
<i>yjiY</i>																							7

FIG. 3. Sixty-one strains with sensitivity to eight or more of the twenty-two antibiotics.




FIG. 4. Strains with sensitivities unique to a particular class of antibiotics and strains with specific sensitivities.

Gene	CIP	ENX	NIT	MTR	SFX	RIF
<i>cedA</i>						
<i>trxA</i>						
<i>trxB</i>						
<i>rpmG</i>						
<i>ydfH</i>						
<i>rhlB</i>						
<i>ybcN</i>						


Gene	Rif	Categ	MIC µg/ml
BW25113			16
<i>bamB</i>		2	1.5
<i>yciM</i>		7	1.5
<i>rfaD</i>		2	3
<i>rfaE</i>		2	3
<i>hlpA</i>		2A	3
<i>surA</i>		2A	3
<i>rpmF</i>		3	3
<i>ylcG</i>		6	3
<i>recA</i>		1	5
<i>rfaC</i>		2	5
<i>tolR</i>		2	5
<i>trxA</i>		2	5
<i>trxB</i>		2	5


Gene	MTR	Categ	MIC µg/ml
BW25113			1000
<i>gshA</i>		1A	100



# Applications

- Targets for co-drugs
- Typing of antibiotics
- Identify mutants for antibiotic detection





## Rif<sup>r</sup> Mutagenic Potency

(ratio to untreated WT)

EMS	5800
5BdU	5100
UV	400
2AP	160
<i>mutS</i>	120
CPR	1-3
WT	1



**Table 1. Mutation frequency of heat/acid-treated M13mp2 DNA in normal and SOS-induced cells**

UV dose, J/m <sup>2</sup>	Lethal hits per DNA molecule	Mutation frequency ( $\times 10^{-4}$ )	Relative mutation frequency
0	0.0	6.2 $\pm$ 1.4	1.0
0	3.2	13.6 $\pm$ 3.0	2.2
100	0.0	11.8 $\pm$ 4.0	1.9
100	3.2	97.8 $\pm$ 25.3	15.8

The transfections, using *E. coli* CSH50 F' *lacZ* $\Delta$ M15, used either undamaged DNA (0.5–2.0  $\mu$ g) or heat/acid-treated DNA (5.0–20  $\mu$ g). Values shown are mean  $\pm$  SD of six independent experiments, all carried out with a single M13mp2 viral DNA preparation. Survival of the UV-irradiated cells was 55  $\pm$  12%.



LB

Cipro .05

Cipro .1

Cipro .2


Cipro .5

Cipro 1

*WT:tolCrecC*

ng/ml





Starting Mix

Day 2 in 15 ng/ml cipro

Day 3 in 15 ng/ml cipro

# Acknowledgments

Hanjing Yang\*

Cindy Tamae

Katherine Tran

Emily Wu\*

Elinne Becket\*

Ann Bui

Frank Chen

Laney Chinn

Amie Fong\*

Kevin Frew\*

Lucia Guisado\*

Jeeyoon Hong

Katherine Kim

Catherine Lee

Kim Lee

Anne Liu

Maria Maiz\*

Leah Medrano\*

Eunice Park

Lillian Tran

Daniel Sitz

Jessica Yuan\*

Christine Wahba

## Bicyclomycin

Max E. Gottesman

Robert S. Washburn

Columbia University  
Medical Center  
New York, NY

## Bioluminescent Proteins

Robert M. Hoffman


Anticancer, Inc.  
San Diego, CA

Anya Salih

University of  
Western Sydney  
New South Wales,  
Australia







## **Damage Avoidance**

- **Detoxification**

## **DNA Damage**

- **Direct Reversal**
- **Excision Repair**
- **Oxidative Damage Repair**
- **Glycosylases**

## **DNA Replication**


- **Pool size**
- **Polymerases**
- **Proofreading**
- **Induction of error-prone polymerases**

## **Post Replication**

- **Mismatch repair**
- **Recombination repair**







LB

Cipro 1

Cipro 2

Cipro 3

Cipro 4

Cipro 5

*WT:tolC*

ng/ml




# Plate Test

- Mixture of wild-type and sensitive mutant
- Antibiotic applied to center of plate
- Concentration gradient, killing in center
- No killing on outer rim of plate
- Selective killing at low concentration generates ring of wild-type cell color



# Previous Approach - Inactivate Genes




- **Knockout repair or other system**
- **Found many repair genes**
- **Many as mutators**


# Finding mutators by papillation

1. Rich medium + lactose


2. Revertants to  $\text{Lac}^+$  make new microcolonies or papillae




3. Mutators have more papillae



WT




mutator






# Look for specific base changes in *lacZ*



GC → TA

Lac<sup>-</sup> → Lac<sup>+</sup>



# Identification of *MutY* and *MutM* in *E.coli*

**The *mutY* gene: a mutator locus in *Escherichia coli* that generates G.C---T.A transversions.**

**Nghiem Y, Cabrera M, Cupples CG, Miller JH**

Department of Biology, University of California, Los Angeles 90024.

We have used a strain with an altered *lacZ* gene, which reverts to wild type via only certain transversions, to detect transversion-specific mutators in *Escherichia coli*. Detection relied on a papillation technique that uses a combination of beta-galactosides to reveal blue Lac<sup>+</sup> papillae. One class of mutators is specific for the G.C--T.A

*PNAS* 1988

***mutM*, a second mutator locus in *Escherichia coli* that generates G.C---T.A transversions.**


**Cabrera M, Nghiem Y, Miller JH.**

Department of Biology, University of California, Los Angeles 90024.

We used strains carrying specific *lacZ* alleles to identify a new mutator locus in *Escherichia coli* which generates only G.C--T.A transversions among base substitutions. The locus, *mutM*, mapped near the *cysE* locus, which is at 81 min on the genetic map.

*J Bacteriol* 1988

# MutY prevents G to T mutations in *E.coli*





Mutation frequency of *mutM*, *mutY*, and *mutM mutY* strains


Strain	No. of Lac <sup>+</sup> revertants	No. of Rif <sup>r</sup> colonies
CC104	3	5-10
CC104 <i>mutM</i>	25	151
CC104 <i>mutY</i>	62	290
CC104 <i>mutM mutY</i>	1900	8200
CSH115 ( <i>mutS</i> )	ND	760
CSH116 ( <i>mutD</i> )	ND	4900



## Oxidative DNA damage repair



**7,8-dihydro-8-oxoguanine (8-oxoG or GO)**





# Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumors.

Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, Hodges AK, Davies DR, David SS, Sampson JR, Cheadle JP.


Institute of Medical Genetics, University of Wales College of Medicine, Heath Park, Cardiff, CF14 4XN, UK.

Inherited defects of base excision repair have not been associated with any human genetic disorder, although mutations of the genes mutM and mutY, which function in Escherichia coli base excision repair, lead to increased transversions of G:C to T:A. We have studied family N, which is affected with multiple colorectal adenomas









**Studies of mutagenesis and repair  
in  
*Bacillus anthracis***

# ***B. anthracis* genes (absent in *E. coli*) that are possibly involved in DNA replication, recombination, and repair**

BAS number	COG	Predicted function
BAS0234	COG4294	UV-endonuclease, putative
BAS5196	COG4294	UV-endonuclease, putative
BAS1439	COG1573	uracil-DNA glycosylase family protein (BAS5250, 2 <sup>nd</sup> UDG)
BAS4536	COG0827	hypothetical protein (putative adenine-specific DNA methylase)
BAS0852	COG1041	hypothetical protein (predicted DNA modification methylase)
BAS3332	COG2176	exonuclease family protein (putative dnaQ homolog)
BAS3404	COG2176	DNA polymerase, epsilon subunit, putative
BAS3669	COG2176	DNA polymerase, alpha subunit, Gram-positive type
BAS4780	COG2176	sporulation inhibitor KapD
BAS4451	COG1039	ribonuclease HIII
BAS2504	COG1372	intein homing endonuclease-related protein
BAS4109	COG1533	spore photoproduct lyase
BAS0039	COG1658	primase-related protein
BAS4858	COG1658	Toprim domain protein


BAS number	COG	Predicted function
BAS1831	COG1793	lipoprotein, putative (putative DNA ligase)
BAS4448	COG1796	PHP domain protein (polymerase X)
BAS0826	COG2094	methylpurine-DNA glycosylase family protein
BAS1291	COG2887	hypothetical protein (very little homology to RecB)
BAS2046	COG3547	transposase, IS110 family, OrfA
BAS2047	COG3547	transposase, IS110 family, OrfB
BAS4475	COG3611	DNA replication protein DnaB
BAS3807	COG3747	hypothetical protein (putative terminase)
BAS1060	COG3857	ATP-dependent nuclease, subunit B
BAS0424	COG3935	prophage LambaBa04, DnaD replication protein, putative
BAS0879	COG3935	DnaD domain protein
BAS1455	COG3935	DNA replication protein DnaD
BAS3088	COG3935	DnaD domain protein
BAS3828	COG3935	prophage LambaBa02, DNA replication protein
BAS5042	COG4095	comF operon protein 1
BAS2732	COG4912	hypothetical protein (predicted DNA alkylation repair enzyme)
BAS3091	COG4912	hypothetical protein (predicted DNA alkylation repair enzyme)
BAS4783	COG4912	hypothetical protein (predicted DNA alkylation repair enzyme)



# Unique detoxification enzymes in *B. anthracis*

- 5 catalases
- 3 Fe-Mn superoxide dismutase
- 1 cytoplasmic Cu-Zn superoxide dismutase
- 1 bromoperoxidase
- 1 thioperoxidase
- 8 thioredoxin proteins

## *B. anthracis* knockout strategy



## ***B. anthracis* knockout mutants constructed**

*mutS* (DNA mismatch repair protein)

*mutY* (A/G-specific adenine glycosylase)

*mutM* (formamidopyrimidine-DNA glycosylase)

*mutM*, *mutY*

*ndk* (nucleoside diphosphate kinase)


*ndk*, *mutS*







bromoperoxidase





***B. Anthracis rpoB* mutation  
frequencies ( $f$ ) and rates ( $\mu$ )  $\times 10^9$**

	<u><math>f</math></u>	<u><math>\mu</math></u>
Wild type	2.8 (1.7-4.7)	1.6 (1.2-2.3)
<i>mutY</i>	33 (31-56)	9.4 (9.0-14)
<i>mutY, M</i>	2800 (2500-3300)	430 (390-500)
<i>mutS</i>	500 (480-550)	87 (84-94)













**E**



milk agar (37°C, O/N)



**A****B****C**

**Fig. 3.** A–C. Photographs showing two transposon-insertion mutants T17D7 and T17D10 (marked with black arrows), which display similar phenotypes as the group A papillation mutants. D–E. photographs of cells harbouring pUTE29 or pUTE29*nprR* on LB and milk plates.


**C**

A. On the LB plate.






B. On the sporulation (SM) plate.

C. On the milk plate.

**D****C****D****C****D**

**A**

control

SV17D9 (*mutS*)T6F8 (*mutL*)**B**SV15A9 (*yycH*)T18F4 (*yycI*)SV13G6 (*yycJ*)**C****D**

## Mutations in *nprR*

Type of change	Occurrence
Base substitutions	17
Small insertions and deletions	21
Tandem duplications	3
Large deletions	17
Total	58

## 80 bp tandem duplication

wild type

AGAG**GTTAT** TGTGC.....CAAG**GTTAT** CATGAAACAGGCCTATATTA

80 bp

*nprR* mutant

AGAG**GTTAT** TGTGC.....CAAG**GTTAT** TGTGC.....CAAG**GTTAT** CATGA

80 bp

80 bp

## 204 bp large deletion

wild type

TTTGCT**GATAAGG** ATGTACT.....ATTAAT**GATAAGG** GAATTGATGCAGCAAA

204 bp

*nprR* mutant

TTTGCT**GATAAGG** GAATTGATGCAGCAAAACAAGAAGAGAGGTTTAATGCAAAATTA

**Table 5.** Tandem duplications detected in the *recJ* mutants.

No.	BAS0566	Occurrence <sup>a</sup>	
1	333–339, 7 bp	17	ATTTTGAAATTAT
2	921–963, 43 bp	12	TAGATTTAAATTA
3	237–244, 8 bp	4	GCTGGATGAATG
4	588–644, 57 bp	4	ATTATAATATAGC
5	1011–1060, 50 bp	4	GGGAATTGATGC
6	222–237, 16 bp	3	GGATGTGAAGGG
7	401–420, 20 bp	3	CACTTGAAGAAG
8	336–345, 10 bp	2	TTGAAATTATAAA
9	338–347, 10 bp	2	GAAATTATAAATT
10	384–426, 43 bp	2	GAAAAGGGATAT
11	425–435, 11 bp	2	TGAAGAAGGTAT
12	463–500, 38 bp	2	GTTATTATA TATG
13	616–630, 15 bp	2	TTAGATATTCAT
14	968–999, 32 bp	2	TTAAATTAGAAG
15	87–220, 134 bp	1	ATTATGTCAGGG
16	133–140, 8 bp	1	AATGGAAAGATC
17	213–223, 11 bp	1	TGTAGAAGAGGA
18	225–304, 80 bp	1	TGTGAAGGGGAA
19	230–237, 8 bp	1	AGGGGAAGCTGG
20	326–385, 60 bp	1	GTTTTGGATTTG
21	418–504, 87 bp	1	AGATAGATTGAAG
22	422–508, 87 bp	1	AGATAGATTGAAGAAGG
23	509–554, 46 bp	1	ATGGAAGGAGG
24	599–670, 72 bp	1	CGCTTGTATATA
25	736–781, 46 bp	1	AAAGGTCAGTAT
26	809–821, 13 bp	1	GATGTACTTTTAG
27	821–900, 80 bp	1	GCTATTACTTTAA
28	1038–1060, 23 bp	1	GAGGTTTAATGC
29	1136–1172, 37 bp	1	CGTTGTATAAAT
Total		76	

a. Tandem duplications detected in *recJ* and *recJ'* mutants.

b. Tandem duplication sequences are underlined. Short homologous sequences are in



## List of identified *Bacillus anthracis* mutator genes and their functions

---

No.	ORF	Product
-----	-----	---------

---

Genes previously identified to be mutagenic when disrupted:

1	<i>mutS</i>	DNA mismatch repair protein MutS
2	<i>mutL</i>	DNA mismatch repair protein MutL
3	<i>mutY</i>	A/G-specific adenine glycosylase
4	<i>poll-mutM</i>	DNA polymerase I formamidopyrimidine-DNA glycosylase

Additional genes identified in this study:

5	<i>yycJ</i>	metallo-beta-lactamase family protein
6	<i>BAS4289</i>	helicase, putative
7	<i>recJ</i>	single-stranded-DNA-specific exonuclease

---

# Distribution of mutations leading to Rif<sup>r</sup> in *B. anthracis*

<i>B. anthracis</i> site (bp)*	Amino acid change	Base-pair change	Spontaneous		<i>mutS</i>	<i>mutY</i>	<i>mutY</i> <i>mutM</i>	5AZ	MNNG
1361	Q454R	AT→GC	15	24*	19	0	0	0	0
1400	H467R	AT→GC	17	23*	20	0	0	0	2
1399	H467Y	GC→AT	20	23*	1	0	0	0	31
1349	S450F	GC→AT	0	0	0	0	0	0	0
1415	S472F	GC→AT	1	4*	0	0	0	0	8
<b>1415</b>	S472Y	GC→TA	1	1	0	10	0	0	0
1360	Q454K	GC→TA	1	2*	0	27	30	0	0
<b>1361</b>	Q454L	AT→TA	0	0	0	0	0	0	0
<b>1375</b>	T459S	AT→TA	0	0	0	0	0	0	0
1402	K468Q	AT→CG	0	0	0	0	0	0	0
1400	H467P	AT→CG	1	1	0	0	0	0	0
1349	S450C	GC→CG	0	0	0	0	0	0	0
1399	H467D	GC→CG	0	0	0	0	0	17	0
1558	S453C	GC→CG	0	0	0	0	0	0	0
<b>Total</b>	<b>14</b>		<b>56</b>	<b>78*</b>	<b>40</b>	<b>37</b>	<b>30</b>	<b>17</b>	<b>41</b>

Table 1. *B. anthracis rpoB* mutation frequencies and rates.

Genotype	f x 10 <sup>9</sup>
wild type	2.8 <sup>a</sup> (1.7–4.7) <sup>b</sup> , 12 <sup>c</sup> (8-18)
MUT1E1 ( <i>recD2</i> )	477 <sup>c</sup> (377-555)
BAS4289' ( <i>recD2</i> )	538 <sup>c</sup> (435-866)
BAS1146 ( <i>uvrD</i> )	20 <sup>c</sup> (10-47)
BAS3618 ( <i>mutS</i> )	500 <sup>a</sup> (480-550)

<sup>a</sup>The value was taken from Zeibell et al 2007.

<sup>b</sup>Values in parentheses are 95% confidence limits (Dixon and Massey, 1969).

<sup>c</sup>The value was obtained in this study.


# Acknowledgement

Hanjing Yang  
Sharon Anguila  
Krystal Ziebell  
Cindy Tamae  
Tarmar Sardarrian  
Martha Pastuszka  
Madeline Yung  
Cameron Sikavi


Anne Liu  
Katherine Kim  
Bindu Patel  
Vivian Shi  
Andrea Chan  
Hannah Hong  
Jennifer Lee  
Aileen Chang

**F**


LB agar (Day 6), cell patch center



LB agar (Day 6), cell patch edge



SM agar (Day 6), cell patch center





# Search for New Mutational Pathways



# Brazilian amputee model dead at 20



## •STORY HIGHLIGHTS

- NEW:** Brazilian amputee model Mariana Bridi da Costa died early Saturday
  - Da Costa's hands, feet were amputated after she contracted septicemia
  - Da Costa placed sixth in the Miss Bikini International competition in China

# Family Mourning MRSA Death Of Frankford Teen



Reporting  
Valerie  
Levesque

PHILADELPHIA (CBS 3) — A local family is speaking out after they say their young son died of the highly contagious infection MRSA.

Michael Leterski was a 13-year student at the Ethan Allen Elementary School and a Frankford resident. His family thought he had a bad cold or the flu until he died February 16.

"All of a sudden, he just said 'it's time' and blood just started pouring out of his mouth and he was gone in my arms and my son was doing CPR on him," Michael's grandmother Mary Ann Gwaltney said.

The family told CBS3 that the medical examiner's office did an autopsy.

"They took a part of the lung and put it in the machinery and found out it was MRSA," Mary Ann said. "He was a perfectly healthy, normal 13-year-old boy looking to graduate from school, and just wiped out of our arms."



◀ 1 of 1 ▶

[Click to enlarge](#)

A Frankford family says their son, Michael Leterski, died of MRSA.  
CBS

## Related Slideshows



[World Welcomes Mardi Gras 2009](#)



[Red Carpet Fashions At 81st Academy](#)



*Staphylococcus aureus*



*Mycobacterium tuberculosis*




*Acinetobacter baumannii*



*Pseudomonas aeruginosa*

# Problem

- We are losing the war on antibiotics
- Need to find new antibiotics/treatments
- Need to change behavior






# Resistance Mechanisms


Altered receptors for  
the drug

Decreased entry into  
the cell

Destruction or  
inactivation of the  
drug




# Route of Pharmaceuticals Entering Our Environment



# Some Statistics

- more than 70 percent of the bacteria that cause hospital-acquired infections are resistant to at least one of the antibiotics most commonly used to treat them.
- Many infectious diseases are increasingly difficult to treat.
- Over 2 million fall prey to microbes once they get in the hospital, in this country alone. Some 90,000 die. About 70 percent of those are infected by drug-resistant bacteria. Costs for treatment of these infections approach \$5 billion a year. Overall, the yearly toll exacted by drug-resistant infections in the United States is estimated to exceed \$30 billion.



In the USA, more people die from MRSA than from AIDS

- In 2005
  - 20,000 people died from MRSA
  - 17,000 people died from AIDS



# Statistics


- Farm animals in the United States receive 24.6 million pounds of antibiotics a year, which may be fueling the rise of drug-resistant bacteria, according to the Union of Concerned Scientists (UCS). UCS noted that about 70 percent of all antibiotics made in the United States are used to fatten up livestock.

- Source: “Hogging It: Estimates of Antimicrobial Abuse in Livestock,” by Margaret Mellon, Charles Benbrook, and Karen Lutz Benbrook, Union of Concerned Scientists, January 2001 (report available at [www.ucsusa.org](http://www.ucsusa.org)).



# Approaches


- Find new antibiotics from natural sources
- Make chemical derivatives of existing antibiotics
- Find new targets in cell
- Find new combinations of existing drugs
- Find co-drug targets and co-drugs (potentiators)
- Exploit genomics – total knockout collections, metabolomic simulations



A successful example of a drug plus co-drug combination is the use of  $\beta$ -lactamase inhibitors together with  $\beta$ -lactams, such as penicillin



# Vancomycin



Strain A=WT (yellow)

Strain B=Drug sensitive mutant (purple)

starting mixture

1:20 Strain A: Strain B  
purple



growth without drug



growth in presence of  
drug: strain B inhibited by  
low concentration of drug

